Watson
This article was originally published in The Tan Sheet
Executive Summary
Firm receives ANDA approval for 2 mg and 4 mg formualtions of mint-flavored nicotine polacrilex gum, bioequivalent to GlaxoSmithKline's Nicorette Mint...
You may also be interested in...
Watson 483
Firm says it is taking appropriate steps to remedy FDA observations in a 483 good manufacturing practices report regarding laboratory test messages and documentation procedures after an inspection of its Corona, Calif. manufacturing plant March 31 through May 6. Watson recently received ANDA approval for 2 mg and 4 mg nicotine polacrilex gum, equivalent to GlaxoSmithKline's mint-flavored Nicorette (1"The Tan Sheet" Aug. 2, 2004, In Brief)...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.